{"id":"W4386102828","doi":"10.1016/s0140-6736(23)01245-x","title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"MacroGenics; Puma Biotechnology; Mylan; Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Hazard ratio; Taxane; Cancer; Clinical trial; Confidence interval","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003062778,0.001551281,0.001634733,0.0004300499,0.0003435331,0.001071496,0.0009080648,0.001371801,0.003872701],"category_scores_gemma":[0.001493895,0.0004007251,0.001618353,0.0005348333,0.001228543,0.0008489292,0.0005305265,0.002429747,0.0005691707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001284747,"about_ca_system_score_gemma":0.001370327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001093079,"about_ca_topic_score_gemma":0.002866457,"domain_scores_codex":[0.999189,0.0005221249,0.0000307639,0.0001013945,0.00005451412,0.000102273],"domain_scores_gemma":[0.9989447,0.000200832,0.0002846257,0.00008550457,0.00006043035,0.0004240324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9740175,0.006686565,0.001157255,0.0003012412,0.0004091988,0.00004382781,0.00007517354,0.0008276021,0.004448208,0.00008604497,0.0008038576,0.01114351],"study_design_scores_gemma":[0.8749405,0.1207858,0.002547906,0.00001993637,0.000196874,0.00006162505,0.00002110026,0.0003313296,0.0004582464,0.0001012099,0.0005251836,0.00001029404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948716,0.00141594,0.0001745879,0.0002773885,0.0001252037,0.001601904,0.0005438508,0.000039377,0.0009500538],"genre_scores_gemma":[0.9928612,0.001012452,0.0006116125,0.0005210999,0.0001792884,0.002288861,0.001187151,0.0000171305,0.001321123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003872701,"threshold_uncertainty_score":0.01619774,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05675231104043848,"score_gpt":0.3583262430471858,"score_spread":0.3015739320067473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}